

## Lecture Abstract or Synopsis for publication

### The Additional Benefits of Anagliptin Beyond Glycemic Control

**Jun Hwa Hong**<sup>1\*</sup>

<sup>1</sup> Department of Internal Medicine, Division of Endocrinology, Eulji University Hospital, Korea  
*lammoth@eulji.ac.kr*

#### **Abstract**

---

DPP-4 inhibitors lower blood glucose level by increasing GLP-1 which inhibits glucagon secretion and increases insulin release; low hypoglycemia risk

Blood glucose reduction effect of Anagliptin : Administered twice a day

- 1) Steady glycemic control - well-adapted for modern day high-calorie dinner
- 2) Significantly decreased glycemic variability
- 3) Effective glucose reduction when using combination therapy with other classes of anti-diabetic drugs or insulin injections

Lipid lowering effect of Anagliptin :

- 1) LDL-C reduction, decreases SREBP-2 mRNA expression (important in cholesterol synthesis in the liver)
- 2) Decreases ApoB-100 production (necessary in VLDL, LDL synthesis)
- 3) Ameliorates arterial stiffness (CAVI) by reducing RLP-C and visceral fat

Renoprotective effect of Anagliptin:

Strong renoprotective effect compared to other DPP-4 inhibitors.

#### **Keywords**

---

*Anagliptin, DPP4 inhibitor, Glucose, Glucagon, LDL*